Document the product claims versus what was delivered
These temperature-sensitive injectable treatments for type 2 diabetes and weight management must be stored correctly, transported safely, and administered on schedule, even when crossing time zones
These combinations have been shown to enhance weight, glycemic, and cardiometabolic outcomes while potentially reducing GI side effects
2 The addition of semaglutide to the Food and Drug Administration (FDA) shortage list from 2022 to February 2025, and tirzepatide to the same list from 2022 to December 2024, gave compounding pharmacies permission by the FDA to produce exact duplicates to ensure continuity of treatment until production met demand
Some studies indicate that aligning eating windows with circadian rhythms could affect hormone responses, but this area requires further investigation before specific recommendations can be made
Most bloating is mild and temporary